Annual Meeting of The Endocrine Society (ENDO 2019)

New osteoporosis guideline: Who to treat with what

Elvira Manzano, 20190429110000

A new osteoporosis guideline by the Endocrine Society puts a premium on women at high risk of fractures, particularly those who have had a recent fracture after menopause, and outlines the latest pharmacologic options for specific patient groups.

Walking downhill after meals osteoprotective?

Elvira Manzano, 20190427130000

Walking downhill within 1 hour after meals may help reduce bone resorption in postmenopausal women with diabetes, according to new research. Walking uphill does not provide the same osteogenic response.

Novel vaginal ring effectively prevents unwanted pregnancy

Novel vaginal ring confers sustained pregnancy prevention up to a year

Pearl Toh, 20190417190010

A contraceptive vaginal system (Annovera) releasing a combination of segesterone acetate and ethinyl estradiol (SA/EE) effectively inhibits ovulation up to a year even at low systemic levels of SA, reports a review study presented at ENDO 2019.

Oral semaglutide trumps sitagliptin in reducing HbA1c, weight in uncontrolled T2D

Roshini Claire Anthony, 20190417140307

Individuals with poorly controlled type 2 diabetes (T2D) had greater HbA_1c reductions and weight loss when a 7 or 14 mg/day dose of the GLP-1* receptor agonist semaglutide rather than sitagliptin was added to their background diabetic medications, results of the phase IIIa PIONEER 3** trial showed.

Osilodrostat shows promise for Cushing’s Disease

Pearl Toh, 20190415190010

Treatment with the oral 11β-hydroxylase inhibitor osilodrostat continues to maintain a normalized mean urinary free cortisol (mUFC) in patients with Cushing’s Disease (CD) in a phase III trial presented at ENDO 2019.

Sustained weight loss with testosterone therapy in obese men with hypogonadism

Roshini Claire Anthony, 20190415140303

Long-term testosterone therapy in obese men with hypogonadism led to sustained weight loss and improvements in multiple anthropometric parameters, according to an observational study presented at ENDO 2019.

Male contraceptive pill breaks new ground in the birth control field

Audrey Abella, 20190411100000

The novel androgen 11-beta-methyl-19-nortestosterone dodecylcarbonate (11β-MNTDC) – a modified testosterone with androgenic and progestational activity being developed as a male contraceptive – effectively suppressed endogenous gonadotropin and testosterone production in healthy men, consequently preventing pregnancies, according to data presented at ENDO 2019.

Fertility potential retained in trans men post-testosterone therapy

Audrey Abella, 20190409100000

Ovarian function in transgender men remained well-preserved even after a year of testosterone treatment, providing hope for trans men who would like to bear children in the future, according to data presented at ENDO 2019.

Migraine frequency, intensity reduced with weight loss

Roshini Claire Anthony, 20190405140303

An additional benefit of weight loss among individuals with obesity may be the reduction in severity and frequency of migraines, a study presented at ENDO 2019 showed.

Faulty sperm a marker for repeat miscarriages

Audrey Abella, 20190405100000

Sperm appears to play a role in repeat miscarriages, as elevated levels of semen reactive oxygen species (ROS), elevated sperm DNA fragmentation, and a lower percentage of normal morphology were found in male partners of women with idiopathic recurrent pregnancy loss* (RPL), according to data presented at ENDO 2019.